Background <p>The diagnosis of acid sphingomyelinase deficiency (ASMD, Niemann Pick Type A, A/B, B) is frequently delayed by years, because of its heterogeneous and often unspecific clinical features. The involvement of multiple organs including the musculoskeletal and central nervous systems, poses a challenge for accurate diagnosis. To address this, we developed a suspicion index tool (SIT) for healthcare professionals to enable early and accurate diagnosis of ASMD.</p> Methods <p>Our methodological approach encompasses five key steps: (i) literature research on ASMD symptomatology, (ii) retrospective expert chart review of international ASMD centers, (iii) retrospective statistical analysis, (iv) development of an individual risk prediction score via random forest regression, and multinomial modeling, (v) internal validation of the tool via bootstrap resampling.</p> Results <p>Data were collected from 908 patients (48 cases, 52 controls, and 808 non-cases) from eight expert centers. Visceral symptoms emerged as strong indicators of ASMD, particularly isolated unexplained splenomegaly (100% of cases vs. 71% of controls and 0.4% of non-cases) and hepatomegaly (92% of cases vs. 56% of controls and 0.4% of non-cases). Respiratory symptoms, thrombocytopenia, and hypercholesterolemia were also identified as significant indicators. These variables were selected for inclusion in the final SIT using a best subset selection algorithm. Each variable composition was evaluated via extensive repetitions. Additionally, expert input was sought to assess the significance of selected variables. The SIT demonstrated superior accuracy, sensitivity, specificity, and internal validity, confirming its reliability.</p> Conclusions <p>The SIT is currently under development as a web-based platform for facilitating the diagnosis of ASMD and other treatable diseases in at-risk populations.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

A suspicion index tool to aid the diagnosis and treatment of ASMD

  • Anna-Maria Wiesinger,
  • Georg Zimmermann,
  • Wanda Lauth,
  • Nicole Muschol,
  • Dorothea Möslinger,
  • Vassiliki Konstantopoulou,
  • Sabine Scholl-Bürgi,
  • Daniela Karall,
  • Roberto Giugliani,
  • Eugen Mengel,
  • Elmar Aigner,
  • Daniel Weghuber,
  • Florian B. Lagler

摘要

Background

The diagnosis of acid sphingomyelinase deficiency (ASMD, Niemann Pick Type A, A/B, B) is frequently delayed by years, because of its heterogeneous and often unspecific clinical features. The involvement of multiple organs including the musculoskeletal and central nervous systems, poses a challenge for accurate diagnosis. To address this, we developed a suspicion index tool (SIT) for healthcare professionals to enable early and accurate diagnosis of ASMD.

Methods

Our methodological approach encompasses five key steps: (i) literature research on ASMD symptomatology, (ii) retrospective expert chart review of international ASMD centers, (iii) retrospective statistical analysis, (iv) development of an individual risk prediction score via random forest regression, and multinomial modeling, (v) internal validation of the tool via bootstrap resampling.

Results

Data were collected from 908 patients (48 cases, 52 controls, and 808 non-cases) from eight expert centers. Visceral symptoms emerged as strong indicators of ASMD, particularly isolated unexplained splenomegaly (100% of cases vs. 71% of controls and 0.4% of non-cases) and hepatomegaly (92% of cases vs. 56% of controls and 0.4% of non-cases). Respiratory symptoms, thrombocytopenia, and hypercholesterolemia were also identified as significant indicators. These variables were selected for inclusion in the final SIT using a best subset selection algorithm. Each variable composition was evaluated via extensive repetitions. Additionally, expert input was sought to assess the significance of selected variables. The SIT demonstrated superior accuracy, sensitivity, specificity, and internal validity, confirming its reliability.

Conclusions

The SIT is currently under development as a web-based platform for facilitating the diagnosis of ASMD and other treatable diseases in at-risk populations.